Journal
GLYCOBIOLOGY
Volume 28, Issue 9, Pages 640-647Publisher
OXFORD UNIV PRESS INC
DOI: 10.1093/glycob/cwx108
Keywords
blocking antibodies; cancer immunotherapy; hypersialylation; immune evasion; N-acetyl-neuraminic acid; N-glycolylneuraminic acid
Categories
Funding
- Schoenmakers Foundation
- Goldschmidt-Jacobson Foundation
- Promedica Foundation
- Swiss National Science Foundation (SNSF) [310030_162552/1]
- Swiss Cancer League/Swiss Cancer Research [KFS-3941-08-2016, KFS-3248-08-2013]
Ask authors/readers for more resources
Changes in sialic acids in cancer have been observed for many years. In particular, the increase of sialoglycan density or hypersialylation in tumors has been described. Recent studies have identified mechanisms for immune evasion based on sialoglycan interactions with immunoregulatory Siglec receptors that are exploited by tumor cells and microorganisms alike. Siglecs are mostly inhibitory receptors similar to known immune checkpoints including PD-1 or CTLA-4 that are successfully targeted with blocking antibodies for cancer immunotherapy. Here, we summarize the known changes of sialic acids in cancer and the role Siglec receptors play in cancer immunity. We also focus on potential ways to target these Siglec receptors or sialoglycans in order to improve anti-cancer immunity.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available